Suppr超能文献

冠状动脉搭桥术中的缓激肽预处理

Bradykinin preconditioning in coronary artery bypass grafting.

作者信息

Wei Minxin, Wang Xin, Kuukasjärvi Pekka, Laurikka Jari, Rinne Timo, Honkonen Eva-Liisa, Tarkka Matti

机构信息

Division of Cardiothoracic Surgery, Tampere University Hospital, FIN-33521 Tampere, Finland.

出版信息

Ann Thorac Surg. 2004 Aug;78(2):492-7. doi: 10.1016/j.athoracsur.2003.11.039.

Abstract

BACKGROUND

Experimental studies have shown that activation of bradykinin B2 receptor is one of the most important triggers of ischemic preconditioning. However, the effect of exogenous administration of bradykinin in cardiac surgery is not yet known. The present prospective randomized study was designed to investigate the effect of bradykinin pretreatment in patients undergoing elective coronary artery bypass surgery.

METHODS

Forty-one patients with multiple-vessel coronary artery disease and stable angina, admitted for the first time for elective coronary artery bypass surgery, were randomized into control or bradykinin (BK) groups. Patients in the BK group received bradykinin infusion for 7 minutes (total dose 25 microg) before the initiation of cardiopulmonary bypass. Perioperative cardiac specific troponin I (cTnI) and creatine kinase cardiac isoenzyme (CKMB) release and hemodynamics were recorded.

RESULTS

Bradykinin infusion caused acute decrease of blood pressure in most of the cases and the mean minimum mean blood pressure during bradykinin infusion was 72.7% of the original mean blood pressure (MBP) level (74.7 +/- 7.9 vs 54.4 +/- 12.1 mm Hg, p < 0.01). There were no differences in baseline levels of cTnI and CKMB between the groups. The postoperative cTnI levels were lower than 10 ng/mL in most patients in both groups (18 in the BK group and 15 in the control group). There was no difference in cTnI between the groups. However, patients who received bradykinin released significantly less CKMB than did the controls postoperatively (6 hours, BK, 22.1 +/- 9.5 vs control, 23.6 +/- 12.7 U/L; 12 hours, BK, 19.4 +/- 12.4 vs control, 28.7 +/- 23.8 U/L; 24 hours, BK, 21.5 +/- 14.7 vs control, 35.5 +/- 28.9 U/L; 48 hours, BK, 14.4 +/- 7.5 vs control, 23.5 +/- 13.6 U/L; analysis of variance [ANOVA] for repeated measurement, p = 0.036). Maximum CKMB was also lower in the BK group (22.4 +/- 14.4 vs 37.7 +/- 27.5 U/L, p = 0.044). There was no significant difference between the groups in any of the hemodynamic variables.

CONCLUSIONS

Exogenous bradykinin infusion showed weak cardioprotective effect in the low-risk patients undergoing coronary artery bypass surgery but the dose used in the study caused acute decrease of systemic blood pressure.

摘要

背景

实验研究表明,缓激肽B2受体的激活是缺血预处理最重要的触发因素之一。然而,缓激肽在心脏手术中外源性给药的效果尚不清楚。本前瞻性随机研究旨在调查缓激肽预处理对择期冠状动脉旁路移植术患者的影响。

方法

41例首次因择期冠状动脉旁路移植术入院的多支血管冠状动脉疾病和稳定型心绞痛患者被随机分为对照组或缓激肽(BK)组。BK组患者在体外循环开始前接受缓激肽输注7分钟(总剂量25微克)。记录围手术期心脏特异性肌钙蛋白I(cTnI)和肌酸激酶心脏同工酶(CKMB)释放以及血流动力学情况。

结果

在大多数情况下,缓激肽输注导致血压急性下降,缓激肽输注期间的平均最低平均血压为原始平均血压(MBP)水平的72.7%(74.7±7.9 vs 54.4±12.1毫米汞柱,p<0.01)。两组间cTnI和CKMB的基线水平无差异。两组中大多数患者术后cTnI水平低于10纳克/毫升(BK组18例,对照组15例)。两组间cTnI无差异。然而,接受缓激肽治疗的患者术后释放的CKMB明显少于对照组(6小时,BK组22.1±9.5 vs对照组23.6±12.7 U/L;12小时,BK组19.4±12.4 vs对照组28.7±23.8 U/L;24小时,BK组21.5±14.7 vs对照组35.5±28.9 U/L;48小时,BK组14.4±7.5 vs对照组23.5±13.6 U/L;重复测量方差分析[ANOVA],p = 0.036)。BK组的最大CKMB也较低(22.4±14.4 vs 37.7±27.5 U/L,p = 0.044)。两组间任何血流动力学变量均无显著差异。

结论

外源性缓激肽输注对接受冠状动脉旁路移植术的低风险患者显示出较弱的心脏保护作用,但研究中使用的剂量导致全身血压急性下降。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验